Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils

被引:143
作者
White, JR
Imburgia, C
Dul, E
Appelbaum, E
ODonnell, K
OShannessy, DJ
Brawner, M
Fornwald, J
Adamou, J
Elshourbagy, NA
Kaiser, K
Foley, JJ
Schmidt, DB
Johanson, K
Macphee, C
Moores, K
McNulty, D
Scott, GF
Schleimer, RP
Sarau, HM
机构
[1] SMITHKLINE BEECHAM, DEPT BIOPHARMACEUT SCI, KING OF PRUSSIA, PA USA
[2] SMITHKLINE BEECHAM, DEPT PULM PHARMACOL, KING OF PRUSSIA, PA USA
[3] SMITHKLINE BEECHAM, DEPT PHARMACOL, HARLOW, ESSEX, ENGLAND
[4] JOHNS HOPKINS ASTHMA & ALLERGY CTR, BALTIMORE, MD USA
关键词
chemotaxis; asthma; expressed tag; sequencing; EST; MPIF-2; CK beta-6; CCR3; eotaxin; eotaxin-2;
D O I
10.1002/jlb.62.5.667
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Eotaxin has been found to bind exclusively to a single chemokine receptor, CCR3. Using expression sequence tag screening of an activated monocyte library, a second chemokine has been identified; it was expressed and purified from a Drosophila cell culture system and appears to only activate CCR3. Eotaxin-2, MPIF-2, or CK beta-6, is a human CC chemokine with low amino acid sequence identity to other chemo- kines. Eotaxin-2 promotes chemotaxis and Ca2+ mobilization in human eosinophils but not in neutrophils or monocytes. Cross-desensitization calcium mobilization experiments using purified eosinophils indicate that eotaxin and MCP-4, but not RANTES, MIP-1a, or MCP-3, can completely cross-desensitize the calcium response to eotaxin-2 on these cells, indicating that eotaxin-2 shares the same receptor used by eotaxin and MCP-4. Eotaxin-2 was the most potent eosinophil chemoattractant of all the chemokines tested. Eotaxin-2 also displaced I-125-eotaxin bound to the cloned CCR3 stably expressed in CHO cells (CHO-CCR3) and to freshly isolated human eosinophils with affinities similar to eotaxin and MCP-4. I-125-Eotaxin-2 binds with high affinity to eosinophils and both eotaxin and cold eotaxin-2 displace the ligand with equal affinity. Eotaxin and eotaxin-2 promote a Ca2+ transient in RBL-2H3 cells stably transfected with CCR3 (RBL-2H3-CCR3) and both ligands cross-desensitized the response of the other but not the response to LTD4. The data indicate that eotaxin-2 is a potent eosinophil chemotactic chemokine exerting its activity solely through the CCR3 receptor.
引用
收藏
页码:667 / 675
页数:9
相关论文
共 50 条
[41]  
SCHLEIMER RP, 1989, J PHARMACOL EXP THER, V250, P598
[42]   Production of the novel C-C chemokine MCP-4 by airway cells and comparison of its biological activity to other C-C chemokines [J].
Stellato, C ;
Collins, P ;
Ponath, PD ;
Soler, D ;
Newman, W ;
LaRosa, G ;
Li, HD ;
White, J ;
Schwiebert, LM ;
Bickel, C ;
Liu, M ;
Bochner, BS ;
Williams, T ;
Schleimer, RP .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (05) :926-936
[43]  
SUR S, 1993, ALLERGY PRINCIPLES P, P169
[44]   Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin [J].
Uguccioni, M ;
Loetscher, P ;
Forssmann, U ;
Dewald, B ;
Li, HD ;
Lima, SH ;
Li, YL ;
Kreider, B ;
Garotta, G ;
Thelen, M ;
Baggiolini, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (05) :2379-2384
[45]  
VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1
[46]   CHARACTERIZATION AND SPECIES DISTRIBUTION OF HIGH-AFFINITY GTP-COUPLED RECEPTORS FOR HUMAN RANTES AND MONOCYTE CHEMOATTRACTANT PROTEIN-1 [J].
VANRIPER, G ;
SICILIANO, S ;
FISCHER, PA ;
MEURER, R ;
SPRINGER, MS ;
ROSEN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (03) :851-856
[47]   Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung [J].
Venge, J ;
Lampinen, M ;
Hakansson, L ;
Rak, S ;
Venge, P .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1996, 97 (05) :1110-1115
[48]  
WELLER PF, 1991, NEW ENGL J MED, V324, P1110
[49]   PURIFIED INTERLEUKIN-5 SUPPORTS THE TERMINAL DIFFERENTIATION AND PROLIFERATION OF MURINE EOSINOPHILIC PRECURSORS [J].
YAMAGUCHI, Y ;
SUDA, T ;
SUDA, J ;
EGUCHI, M ;
MIURA, Y ;
HARADA, N ;
TOMINAGA, A ;
TAKATSU, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (01) :43-56
[50]  
ZEPEDA EAG, 1996, J IMMUNOL, V157, P5613